<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60383">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01899235</url>
  </required_header>
  <id_info>
    <org_study_id>N-20110015</org_study_id>
    <nct_id>NCT01899235</nct_id>
  </id_info>
  <brief_title>The Treatment of Coronary De-novo Lesions With the Elutax Paclitaxel-eluting Balloon Alone, a Pilot Study</brief_title>
  <acronym>EXPEL</acronym>
  <official_title>The Treatment of Coronary De-novo Lesions With the Elutax Paclitaxel-eluting Balloon Alone, a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aalborg Universityhospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aachen Resonance, Aachen, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aalborg Universityhospital</source>
  <oversight_info>
    <authority>Denmark: Ethics Committee</authority>
    <authority>Denmark: Danish Dataprotection Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomised open-label pilot study to assess the safety and efficacy of treatment with a
      drug eluting balloon alone in coronary de novo lesions). Elective patients requiring PCI to
      coronary de novo lesions in vessels 2.5 mm - 4.0 mm.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow recruitment
  </why_stopped>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Major adverse cardiac events</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <condition>Stable Angina</condition>
  <condition>Coronary Stenosis</condition>
  <arm_group>
    <arm_group_label>Stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>drug eluting stent (Resolute)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>drug eluting balloon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>drug eluting balloon (Elutax)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>drug eluting balloon</intervention_name>
    <arm_group_label>drug eluting balloon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>drug eluting stent</intervention_name>
    <arm_group_label>Stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient ≥ 18years old

          -  Stable angina symptoms

          -  Elective treatment to coronary lesion

          -  Reference vessel diameters of ≥ 2.5mm and ≤ 4.0 mm on visual inspection

        Exclusion Criteria:

          -  Left main stem lesion

          -  Bifurcation lesions

          -  Acute coronary syndrome (UAP, NSTEMI, STEMI)

          -  Cardiogenic shock

          -  Chronic total occlusion

          -  Additional lesions requiring PCI

          -  Platelet count ≤ 50 x 109/mm3

          -  Left ventricular ejection fraction ≤ 30%

          -  Patient life expectancy less than 12 months

          -  Known allergies to aspirin, clopidogrel, prasugrel, heparin, stainless steel,
             intravenous contrast (severe), or paclitaxel

          -  Participation in another investigational drug or device study

          -  Patient unable to give informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 15, 2014</lastchanged_date>
  <firstreceived_date>July 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aalborg Universityhospital</investigator_affiliation>
    <investigator_full_name>Svend Eggert Jensen</investigator_full_name>
    <investigator_title>Associate professor, MD, PhD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
